NASDAQ: TRAW
Traws Pharma Inc Stock

$1.45+0.02 (+1.4%)
Updated Apr 30, 2025
TRAW Price
$1.45
Fair Value Price
N/A
Market Cap
$7.36M
52 Week Low
$1.36
52 Week High
$19.44
P/E
-0.04x
P/B
-0.23x
P/S
61.01x
PEG
N/A
Dividend Yield
N/A
Revenue
$226.00k
Earnings
-$54.67M
Gross Margin
100%
Operating Margin
-24,192.04%
Profit Margin
-24,192%
Debt to Equity
-1.79
Operating Cash Flow
-$30M
Beta
0.73
Next Earnings
May 13, 2025
Ex-Dividend
N/A
Next Dividend
N/A

TRAW Overview

Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine TRAW's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
TRAW
Ranked
#125 of 462

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important TRAW news, forecast changes, insider trades & much more!

TRAW News

Overview

Due Diligence Score

Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TRAW scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

TRAW is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TRAW is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
TRAW's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more TRAW due diligence checks available for Premium users.

Valuation

TRAW fair value

Fair Value of TRAW stock based on Discounted Cash Flow (DCF)

Price
$1.45
Fair Value
$0.95
Overvalued by
52.88%
TRAW is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

TRAW price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.04x
Industry
-162.28x
Market
29.18x

TRAW price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
-0.23x
Industry
4.45x

TRAW's financial health

Profit margin

Revenue
$56.0k
Net Income
$81.9M
Profit Margin
146,298.2%
TRAW's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
TRAW's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$25.0M
Liabilities
$56.6M
Debt to equity
-1.79
TRAW's short-term assets ($24.95M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TRAW's long-term liabilities ($45.06M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TRAW's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TRAW's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$4.0M
Investing
$0.0
Financing
$20.0M
TRAW's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

TRAW vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
TRAWC$7.36M+1.40%-0.04x-0.23x
EVGN$7.36M-3.42%-0.39x-5.07x
APLM$7.27M+2.49%-0.12x1.49x
GNPX$7.00M+3.57%-0.05x4.32x
QNRXD$6.97M+2.87%N/A0.76x

Traws Pharma Stock FAQ

What is Traws Pharma's quote symbol?

(NASDAQ: TRAW) Traws Pharma trades on the NASDAQ under the ticker symbol TRAW. Traws Pharma stock quotes can also be displayed as NASDAQ: TRAW.

If you're new to stock investing, here's how to buy Traws Pharma stock.

What is the 52 week high and low for Traws Pharma (NASDAQ: TRAW)?

(NASDAQ: TRAW) Traws Pharma's 52-week high was $19.44, and its 52-week low was $1.36. It is currently -92.54% from its 52-week high and 6.62% from its 52-week low.

How much is Traws Pharma stock worth today?

(NASDAQ: TRAW) Traws Pharma currently has 5,073,790 outstanding shares. With Traws Pharma stock trading at $1.45 per share, the total value of Traws Pharma stock (market capitalization) is $7.36M.

Traws Pharma stock was originally listed at a price of $1,118,248.88 in Jul 25, 2013. If you had invested in Traws Pharma stock at $1,118,248.88, your return over the last 11 years would have been -100%, for an annualized return of -70.84% (not including any dividends or dividend reinvestments).

How much is Traws Pharma's stock price per share?

(NASDAQ: TRAW) Traws Pharma stock price per share is $1.45 today (as of Apr 30, 2025).

What is Traws Pharma's Market Cap?

(NASDAQ: TRAW) Traws Pharma's market cap is $7.36M, as of May 1, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Traws Pharma's market cap is calculated by multiplying TRAW's current stock price of $1.45 by TRAW's total outstanding shares of 5,073,790.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.